Bradley T. Andresen, PhD, FAHA
My laboratory is primarily interested in the molecular mechanisms underlying hypertension. We examine normal and pathological mechanisms underlying blood pressure control in order to create new and personalized therapies. We are also interested in the molecular target of C-peptide, and the role of some prominent cardiovascular drugs in the treatment and prevention of cancer.
Guru V. Betageri, PhD
My laboratory is interested drug formulation and drug delivery using lipids and liposomes. We strive to enhance the bioavailability of poorly soluble drugs and develop controlled release formulations using polymer and phospholipid combination to reduce the burst release.
Arezoo Campbell, PhD
My areas of expertise are in metal-induced neurotoxicity, neuroinflammation, and oxidative stress. The main focus is to determine how aberrant induction of innate immune responses may accelerate the pathogenesis of neurodegenerative disorders. Currently the lab is investigating the mechanism by which particulate matter, which is present in air pollution, triggers an inflammatory response in the CNS.
Moses Chow, PharmD
My laboratory is interested in translational research (from bench to clinical) with a focus on: 1) development of products for sublingual/mucosal drug delivery that provides convenient and rapid therapeutic effect instead of requiring injection, and 2) development of herbal products to enhanced anticancer drug efficacy and safety by utilizing various mechanisms of herb-drug interactions.
Ying Huang, MD, PhD
My area of research focuses on pharmacogenomics of membrane transporters, which are important for drug absorption, distribution and targeting cancer cells, and their potential relevance to cancer chemotherapy. Additionally we investigate natural products, such as traditional herbal medicines, for their effects on overcoming drug resistance and on cancer chemoprevention.
Cynthia Jackevicius, PharmD, MSc, FCSHP, BCPS
The overall encompassing theme of my research is to investigate the effectiveness of cardiac medications in practice. My research explores the rational use of cardiac medications in practice, by prescribers and by patients, related to evidence, policies, marketing or behavior. Using administrative and clinical databases, I evaluate cardiovascular medication use in practice and these studies are important in giving feedback to clinicians to influence their practice.
Fadi Khasawneh, B.Pharm, PhD
My research is focused on delineating signaling pathways involved in platelet activation, and to investigate their role in the pathogenesis of thrombotic diseases. Another goal is to map the G-protein coupling domains of certain platelet G-protein coupled receptors. Our ultimate goal is to identify novel therapeutic targets for the management of thromboembolic disorders.
Maria Lambros, PhD
Work in Dr. Lambros’ laboratory focuses in the area delivery systems and preformulation. Currently we are focusing in the following areas:
1) Targeted lipid nanoparticles to lung and pancreatic cancers.
2) Novel trans-mucosal delivery.
3) Physicochemical properties of drugs and their effect on delivery.
Anandi Law, B.Pharm, PhD
My scholarly interests are in Outcomes Research and include: studying impact of pharmacist provided services such as DSM and MTM on patients’ clinical, economic and humanistic outcomes; measurement issues in patient-reported outcomes such as health-related quality-of-life and satisfaction; improving usefulness of prescription drug labeling; medication disposal; and innovations in health professions education.
Quang A. Le, PharmD, PhD
My scholarly interests include Health-related Quality of Life (HRQOL) Methodology, Bayesian-Network Models, Health/Pharmaceutical Economic Evaluation, and Decision Making in Healthcare.
Kabirullah Lutfy, B.Pharm, PhD
Our laboratory is interested in to define the role of neuropeptides, and in particular that of nociceptin, opioids, and PACAP, in drug addiction and nociceptive processing. The ultimate goal of our research is to provide useful basic science information that could lay the foundation for the development of effective pharmacotherapy of drug addiction and pain management.
David I. Min, PharmD, MS, FCCP, FASHP
My research has been focused on pharmacogenomics in kidney transplantation.
Arbi Nazarian, PhD
My laboratory examines animal models of opiate and psychostimulant addiction across different developmental stages by using behavioral, pharmacological and cell biological approaches. Concurrently we examine nociceptive processing as it pertains to opiate tolerance at the level of the brain and the spinal cord. We are especially interested in examining the role of diabetes and sex differences in both addiction and nociception.
Stephen O’Barr, PhD
My group studies the roll of inflammation in the central nervous system and is working with a patented compound for the treatment of Alzheimer’s disease. We also study the peripheral immune response and are identifying biomarkers important for the diagnosis and treatment of heart failure.
Peter Oelschlaeger, PhD
We study antibacterial resistance conferred by metallo-beta-lactamases. We investigate how these enzymes function and evolve under the selective pressure of antibiotics using various techniques including site-directed mutagenesis, enzyme kinetics, and molecular modeling.
Olivia Phung, PharmD
I am involved with conducting systematic reviews and meta-analyses in a variety of topics related to metabolic syndrome, but most commonly in diabetes. I have unique training in conducting a specific type of meta-analysis, known as network (or indirect comparison) meta-analysis. I also work closely with the Western Diabetes Institute to conduct studies in the patients seen with their providers.
Sunil Prabhu, B.Pharm, PhD
My laboratory is interested in the chemoprevention of colon and pancreatic cancers. We examine novel drug combinations delivered via nanotechnology-based drug delivery systems. In addition, we examine the mechanistic principles which govern the efficacy of the combination drug regimens. Our major goal is to suppress, reverse and/or eliminate the pre-neoplastic events that are ultimately responsible for progression of these deadly cancers.
David J. Sanchez, PhD
Our group studies the innate immune response to chronic viral infections. In particular, we have focused on how the viral causes of chronic diseases such as AIDS and Kaposi’s Sarcoma are able to persist in a host even in the face of an innate immune response such as the antiviral Type I Interferon response.
Sam Shimomura, PharmD
My research interests are in the area of geriatrics. We examine Medicare Part D and the use of technology by the geriatric patient and in the care of geriatric patients by health care professionals.
Jeffrey Wang, PhD
We are interested in applying the principles of pharmacokinetics, drug metabolism, biopharmaceutics, organic synthesis and pharmaceutical analysis to early-stage drug discovery and development for the prevention and treatment of human diseases including cancer and diabetes.